GIM
JBIO

Glenmede Investment Management’s Jade Biosciences JBIO Stock Holding History

Glenmede Investment Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-53
Closed -$529 – 1464
2025
Q2 		$529 Buy
+53
New +$1.8K ﹤0.01% 1493

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Glenmede Investment Management's JBIO Position: Q3 2025 in Review

Glenmede Investment Management sold out of Jade Biosciences (JBIO) in Q3 2025, closing a stake of 53 shares — an estimated $529 sold.

Glenmede Investment Management first reported a position in JBIO in Q2 2025 and held it in 1 quarter. The position peaked at $529 in Q2 2025. 78 funds tracked by Wall St. Rank hold JBIO as of Q3 2025.

  • Glenmede Investment Management reported no remaining Jade Biosciences position as of Q3 2025 after selling out during the quarter.
  • Glenmede Investment Management sold 53 Jade Biosciences shares in Q3 2025, an estimated $529.
  • Glenmede Investment Management first reported a position in Jade Biosciences in Q2 2025 and held it in 1 quarter.
  • Glenmede Investment Management's Jade Biosciences position peaked at $529 in Q2 2025.
  • 78 funds tracked by Wall St. Rank held Jade Biosciences as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.